BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$8.81-2.87%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
BioCryst aims for full year 2026 revenue between $635M and $660M. They lowered operating expenses guidance to $420M-$440M, showing cost control. The acquisition of Astria Therapeutics expands their pipeline. Restructuring focuses resources on rare disease drugs.
Revenue growth is expected to decline about 12% next year. The company is loss-making with volatile management. Restructuring may disrupt progress and delay new drug launches.
The stock trades about 40% below our fair value near $19. Analysts expect revenue to decline 12% next year. Our view is cautious given mixed execution and restructuring risks.
Breaks if: Acquisition integration fails or pipeline expansion stalls in 2026
Breaks if: Operating expenses exceed $440 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround scenario with a focus on strategic restructuring. The current thesis state is intact, supported by recent strong financial performance despite ongoing challenges.
The market appears to have priced in a low level of fragility, indicating that expectations are somewhat justified. BCRX is seen as cheap compared to its peers, but there is a notable expectations gap.
Management is focused on maintaining revenue guidance while reducing operating expenses, which shows a commitment to cost discipline. However, the company remains loss-making, and there is elevated risk due to the volatile nature of its management.
The long-term thesis hinges on the ability to maintain revenue guidance and manage operating costs effectively. Additionally, the performance of sector bellwethers could influence BCRX's trajectory, as well as broader economic indicators like job reports.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'moderate'.
Yes, our read has strengthened. The latest earnings beat supports the company's 2026 revenue guidance. A strategic shift to external innovation reinforces this positive outlook. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Restructuring delays or disrupts pipeline progress beyond 2026
Breaks if: Annual revenue falls below $635 million in FY26
Continue to target full year 2026 total revenue, including RAPIVAB, between $635 million and $660 million.
In the next 1 to 3 years, BCRX's success will depend on its execution of strategic priorities and external market conditions. Not investment advice.